Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Method and composition for treatment of skeletal dysplasias

a technology for skeletal dysplasia and composition, applied in the field of compositions for the treatment of skeletal dysplasia, can solve the problems of skeletal dysplasia (sd), and achieve the effect of enhancing np stabilization in circulation and increasing stability

Inactive Publication Date: 2010-03-04
HEPACORE LTD
View PDF14 Cites 25 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0023]The present invention also provides NP variants with increased stability.
[0024]The present invention further provides a method to enhance NP stabilization in circulation.
[0030]Alternatively, NP may be conjugated to an agent to prolong its half life in circulation or to a peptide that facilitates translocation across a cell membrane.

Problems solved by technology

Moreover, mutations at various positions in this receptor result in skeletal dysplasias (SD).

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Method and composition for treatment of skeletal dysplasias
  • Method and composition for treatment of skeletal dysplasias
  • Method and composition for treatment of skeletal dysplasias

Examples

Experimental program
Comparison scheme
Effect test

example 1

Ex Vivo Bone Culture

[0079]Femora derived from achondroplasia model mice (Ach369 knock-in mice carry the Gly to Cys mutation at position 369, analogous to position 375 in humans or Ach374 knock-in mice that carry the Gly to Arg mutation at position 374, analogous to position 380 in humans) were dissected from P0 wild type, heterozygote and homozygote littermates and cultured in the presence of natriuretic peptides for 15 days.

[0080]Protocol for bone culture: Femoral bone cultures were performed by excising the hind limbs of mice. The limbs were carefully cleaned from the surrounding tissue (skin and muscles) and the femora exposed. The femora were removed and further cleared from tissue remains and ligaments. The femora were measured for their initial length, using a binocular with an eyepiece micrometer ruler. The bones were grown in 1 ml of medium (α-MEM supplemented with penicillin (100 units / ml), streptomycin (0.1 mg / ml), nystatin (12.5 units / ml), BSA (0.2%), O-glycerophosphate (...

example 2

Natriuretic Peptides Lead to an Increase in the Size of Growth Plate

Morphological and Immunohistological Analysis

[0085]Most of the elongation induced by natriuretic peptides observed in bone culture results from epiphyseal growth and not from elongation of the mineralized diaphysis. Morphological analysis of the cellular composition of the growth plate in treated samples revealed that there is an increase in the size of the proliferative region and in the size of the hypertrophic zone. In addition, there is an area of a cellular matrix similar to that observed in the growth plate of FGFR3 knockout mice. Therefore, there seems to be an increase in proliferation which leads to a larger growth plate.

[0086]Mouse-specific BNP was synthesized and labeled with biotin. Biotinylated BNP was tested in bone culture on bones derived from Achondroplasia mice and shown to induce bone elongation. Nevertheless, a higher concentration of BNP was needed. Histological analysis of the distribution of b...

experiment 3

In vivo Administration

1. IP Administration of Drugs to Achondroplasia Pups

[0088]The fastest growth period for mice is during the first month of life therefore, it is expected that the earlier the experiments are initiated, the greater the influence on growth. The disadvantage of treating such young animals is that there is a limit on volume delivered. Drug delivery cannot be performed intravenously (IV) or by implantation of a continuous delivery device like a pump.

[0089]Animals: Heterozygote mice for the achondroplasia mutation, aged P4-P5, weighing approximately 3.5 gr. were randomly separated into groups of 3 animals / group and ear marked. Animals were distributed 6-7 individuals / cage with one foster mother.

[0090]Materials and Procedure: Animals were injected daily with drug intraperitoneally (IP) in a volume not exceeding 50 μl. This volume can be increased proportionally to weight increase. Animals are weighed and the tail length is measured on day 0 and every 2 days thereafter....

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to a method for the treatment of skeletal dysplasia by administering to a patient a composition comprising a therapeutically effective amount of at least one C-type natriuretic peptide (CNP).

Description

CROSS-REFERENCE TO RELATED APPLICATIONS[0001]This application is a division of U.S. application Ser. No. 11 / 840,631 filed Aug. 17, 2007, which is a division of U.S. application Ser. No. 10 / 664,605 filed Sep. 15, 2003, U.S. Pat. No. 7,276,481, which is a continuation of the U.S. national phase of International application PCT / IL02 / 00229 filed Mar. 20, 2002, which claims the benefit of U.S. application No. 60 / 276,939 filed Mar. 20, 2001. The content of each prior application is expressly incorporated herein by reference thereto.FIELD OF THE INVENTION[0002]The present invention relates to compositions for treatment of skeletal dysplasias, such as achondroplasia, and in particular to pharmaceutical compositions for bone elongation in disorders related to abnormal bone growth comprising natriuretic peptides or natriuretic factors.BACKGROUND OF THE INVENTIONBone Development[0003]Endochondral ossification is a fundamental mechanism for bone formation, whereby cartilage is replaced by bone....

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61F2/00A61K38/17A61K35/12A61K9/10A61KA61K38/00A61K38/22A61K48/00A61P19/00C07K14/58C07K14/61
CPCA61K35/12A61K38/2242A61K48/00A61K35/33C07K14/58C07K14/61C07K2319/02A61K2035/128A61P19/00A61P19/08
Inventor GOLEMBO, MYRIAMYAYON, AVAER
Owner HEPACORE LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com